Display options
Cite
Ohara Y, Chew SH, Misawa N, et al. Connective tissue growth factor-specific monoclonal antibody inhibits growth of malignant mesothelioma in an orthotopic mouse model. Oncotarget. 2018;9(26):18494-18509doi: 10.18632/oncotarget.24892.
Ohara, Y., Chew, S. H., Misawa, N., Wang, S., Somiya, D., Nakamura, K., Kajiyama, H., Kikkawa, F., Tsuyuki, Y., Jiang, L., Yamashita, K., Sekido, Y., Lipson, K. E., & Toyokuni, S. (2018). Connective tissue growth factor-specific monoclonal antibody inhibits growth of malignant mesothelioma in an orthotopic mouse model. Oncotarget, 9(26), 18494-18509. https://doi.org/10.18632/oncotarget.24892
Ohara, Yuuki, et al. "Connective tissue growth factor-specific monoclonal antibody inhibits growth of malignant mesothelioma in an orthotopic mouse model." Oncotarget vol. 9,26 (2018): 18494-18509. doi: https://doi.org/10.18632/oncotarget.24892
Ohara Y, Chew SH, Misawa N, Wang S, Somiya D, Nakamura K, Kajiyama H, Kikkawa F, Tsuyuki Y, Jiang L, Yamashita K, Sekido Y, Lipson KE, Toyokuni S. Connective tissue growth factor-specific monoclonal antibody inhibits growth of malignant mesothelioma in an orthotopic mouse model. Oncotarget. 2018 Apr 06;9(26):18494-18509. doi: 10.18632/oncotarget.24892. eCollection 2018 Apr 06. PMID: 29719620; PMCID: PMC5915087.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2018 Apr 06;9(26):18494-18509. doi: 10.18632/oncotarget.24892. eCollection 2018 Apr 06.

Connective tissue growth factor-specific monoclonal antibody inhibits growth of malignant mesothelioma in an orthotopic mouse model.

Oncotarget

Yuuki Ohara, Shan Hwu Chew, Nobuaki Misawa, Shenqi Wang, Daiki Somiya, Kae Nakamura, Hiroaki Kajiyama, Fumitaka Kikkawa, Yuta Tsuyuki, Li Jiang, Kyoko Yamashita, Yoshitaka Sekido, Kenneth E Lipson, Shinya Toyokuni

Affiliations

  1. Department of Pathology and Biological Responses, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan.
  2. Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan.
  3. Department of Pathology and Laboratory Medicine, Nagoya University Graduate School of Medicine, Nagoya 466-8550, Japan.
  4. Division of Molecular Oncology, Aichi Cancer Center Research Institute, Nagoya 464-8681, Japan.
  5. FibroGen, Inc., San Francisco, CA 94158, USA.
  6. Sydney Medical School, The University of Sydney, Sydney 2006, Australia.

PMID: 29719620 PMCID: PMC5915087 DOI: 10.18632/oncotarget.24892

Abstract

Malignant mesothelioma is an aggressive neoplasm with no particularly effective treatments. We previously reported that overexpression of connective tissue growth factor (CTGF/CCN2) promotes mesothelioma growth, thus suggesting it as a novel molecular target. A human monoclonal antibody that antagonizes CTGF (FG-3019, pamrevlumab) attenuates malignant properties of different kinds of human cancers and is currently under clinical trial for the treatment of pancreatic cancer. This study reports the effects of FG-3019 on human mesothelioma

Keywords: FG-3019 (pamrevlumab); connective tissue growth factor (CTGF); malignant mesothelioma; molecular target therapy; tumor microenvironment

Conflict of interest statement

CONFLICTS OF INTEREST The authors except Kenneth E. Lipson declare that they have no competing interests. FibroGen provided FG-3019 for investigation. FibroGen did not provide any funds for these expe

References

  1. Cancer Res. 2006 Jun 1;66(11):5816-27 - PubMed
  2. Int J Cancer. 2015 Aug 1;137(3):504-11 - PubMed
  3. Clin J Am Soc Nephrol. 2010 Aug;5(8):1420-8 - PubMed
  4. Cell Death Dis. 2014 Oct 23;5:e1485 - PubMed
  5. Environ Sci Technol. 2003 Feb 1;37(3):502-8 - PubMed
  6. Exp Hematol. 2005 Nov;33(11):1402-16 - PubMed
  7. J Exp Med. 2015 Dec 14;212(13):2235-51 - PubMed
  8. Cancer Res. 2009 Apr 15;69(8):3482-91 - PubMed
  9. Clin Cancer Res. 2016 Jun 15;22(12 ):2848-54 - PubMed
  10. J Biochem. 1999 Jul;126(1):137-45 - PubMed
  11. Br J Cancer. 2010 Feb 2;102(3):553-60 - PubMed
  12. Mol Cancer. 2016 Apr 06;15:27 - PubMed
  13. Carcinogenesis. 2014 Jan;35(1):164-72 - PubMed
  14. Invest New Drugs. 2007 Oct;25(5):417-23 - PubMed
  15. Cancer Chemother Pharmacol. 2006 Apr;57(4):401-11 - PubMed
  16. Nat Cell Biol. 2002 Aug;4(8):599-604 - PubMed
  17. Eur Respir J. 2010 Mar;35(3):479-95 - PubMed
  18. J Clin Oncol. 2004 May 1;22(9):1589-97 - PubMed
  19. J Biol Chem. 2004 Dec 31;279(53):55958-68 - PubMed
  20. Cell. 2011 Mar 4;144(5):646-74 - PubMed
  21. Mol Cancer Ther. 2006 May;5(5):1108-16 - PubMed
  22. Int J Cancer. 2013 Jan 15;132(2):459-71 - PubMed
  23. Hum Pathol. 2007 Jul;38(7):986-94 - PubMed
  24. Clin Sci (Lond). 2015 Feb;128(3):181-96 - PubMed
  25. J Thorac Oncol. 2008 Jul;3(7):764-71 - PubMed
  26. Free Radic Biol Med. 2017 May;106:91-99 - PubMed
  27. Cancer Chemother Pharmacol. 2008 Apr;61(4):549-58 - PubMed
  28. Cancer Sci. 2006 May;97(5):387-94 - PubMed
  29. Biochem Biophys Res Commun. 2008 Feb 8;366(2):450-6 - PubMed
  30. Oncogene. 2014 Feb 27;33(9):1093-100 - PubMed
  31. J Exp Med. 2015 Dec 14;212(13):2253-66 - PubMed
  32. Oncogene. 2015 Jan 2;34(1):73-83 - PubMed
  33. J Exp Med. 2012 Mar 12;209(3):479-94 - PubMed
  34. N Engl J Med. 2005 Oct 13;353(15):1591-603 - PubMed
  35. Oncotarget. 2016 Oct 25;7(43):69565-69578 - PubMed
  36. Oncotarget. 2014 Feb 28;5(4):1062-70 - PubMed
  37. Liver Int. 2008 Sep;28(8):1065-79 - PubMed
  38. J Thorac Oncol. 2012 Nov;7(11):1631-9 - PubMed
  39. J Clin Invest. 2010 Sep;120(9):3340-9 - PubMed
  40. Eur Respir J. 2016 May;47(5):1481-91 - PubMed
  41. Cancer Sci. 2018 Feb;109 (2):330-339 - PubMed
  42. Br J Cancer. 2005 Feb 14;92 (3):587-93 - PubMed
  43. J Pathol. 2007 Mar;211(4):439-46 - PubMed
  44. Am J Physiol Lung Cell Mol Physiol. 2014 Apr 15;306(8):L786-96 - PubMed
  45. Proc Natl Acad Sci U S A. 2013 Jul 23;110(30):12325-30 - PubMed
  46. Cancer Sci. 2009 Jan;100(1):9-16 - PubMed
  47. J Pathol. 2014 Aug;233(4):402-14 - PubMed
  48. J Biomed Sci. 2008 Nov;15(6):675-85 - PubMed
  49. Ann Hematol. 2014 Mar;93(3):485-492 - PubMed
  50. Int J Oncol. 2013 Feb;42(2):444-52 - PubMed
  51. Cell Cycle. 2006 Aug;5(15):1597-601 - PubMed
  52. Bone. 2009 Jan;44(1):24-31 - PubMed
  53. Anal Quant Cytol Histol. 2001 Aug;23(4):291-9 - PubMed
  54. J Clin Oncol. 2003 Jul 15;21(14):2636-44 - PubMed
  55. Oncotarget. 2015 Dec 29;6(42):44551-62 - PubMed

Publication Types